ektars proprietary Aerosol Generator that is designed to rapidly deliver aerosolized antibiotics to the deep lungs, both within and outside of a ventilator system. The result is a potentially faster-acting, potentially more effective treatment modality which provides key advantages over traditional pneumatic or ultra-sonic nebulizer.

ABOUT HOSPITAL-ACQUIRED GRAM-NEGATIVE PNEUMONIA:

Hospital-acquired, gram-negative bacterial pneumonia is a serious problem which afflicts patients even in the worlds most advanced clinical settings. It is most commonly acquired by patients in intensive care units who have been put on ventilators for breathing assistance. Current treatment involves the administration of intensive antibiotics, supplemental oxygen, and intravenous fluids. Some 25-50% of those who acquire gram-negative bacterial pneumonia will die from it.

'"/>

Contact: Tim Warner
twarner@nektar.com
650-283-4915
Nektar Therapeutics
9-May-2007


Page: 1 2
Related biology news :

1. 2007-2008 Genzyme/ACMGF Clinical Genetics Fellowship In Biochemical Genetics award winner announced
2. Scientists honored with Excellence in Clinical Research Award
3. Clinical trial for diabetic macular edema
4. The Parkinsons Institute to conduct Phase III Clinical Trial of creatine for Parkinsons disease
5. Research and program highlights of the 2007 Annual Clinical Genetics Meeting, March 21-25, 2007
6. American College of Medical Genetics -- 2007 Annual Clinical Genetics Meeting Announcement
7. October MCP: A special issue on Clinical Proteomics
8. Columbia University Medical Center receives major new NIH Clinical Science investment funds
9. Researchers reverse juvenile diabetes in animal model; Clinical trial FDA approved
10. Clinical trial to test stem cell approach for children with brain injury
11. Vaccine trials inject hope into koalas future